Regulation 5 Amendment of regulation 3 (scope of Regulations: special provisions)I1

United Kingdom

(1)

Regulation 3 is amended as follows.

(2)

In paragraph (12)(d)—

(a)

in paragraph (i) insert “ UK ” before “marketing authorisation”;

F1(b)

after paragraph (i) insert—

“(ia)
the EU marketing authorisation,”.

(3)

In paragraph (15)—

(a)

in sub-paragraph (a) insert “ UK ” before “marketing authorisation”; and

F2(b)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annotations

F1: Reg. 5(2)(b) substituted for reg. 5(2)(b)(c) (31.12.2020 immediately before IP completion day) by The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1488), reg. 1, Sch. 2 para. 2(a)
F2: Reg. 5(3)(b) omitted (3.8.2021) by virtue of The Human Medicines (Amendment) (EU Exit) Regulations 2021 (S.I. 2021/834), regs. 1(2), 3

I1: Reg. 5 in force at 31.12.2020 on IP completion day (in accordance with 2020 c. 1, Sch. 5 para. 1(1)), see reg. 1